Clinical Trials Logo

Clinical Trial Summary

This study evaluates the safety and efficacy of PTX-022 (sirolimus) Topical Gel 3.9% w/w in the treatment of Microcystic Lymphatic Malformations. The participant will receive 3 months of PTX-022 treatment by the end of the study.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05050149
Study type Interventional
Source Palvella Therapeutics, Inc.
Contact Emily Cook
Phone 484-253-1463
Email emily.cook@palvellatx.com
Status Recruiting
Phase Phase 2
Start date September 15, 2021
Completion date December 15, 2022

See also
  Status Clinical Trial Phase
Active, not recruiting NCT00975819 - Safety and Efficacy Study of Sirolimus in Complicated Vascular Anomalies Phase 2
Recruiting NCT06160739 - Role of Sirolimus in Treatment of Microcystic , Mixed Lymphatic and Vascular Malformations
Not yet recruiting NCT06239480 - A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study Evaluating Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations Phase 3